75 / 164
335
38.
van Zandwijk N, Clarke C, Henderson D, et al. Guidelines for the
diagnosis and treatment of malignant pleural mesothelioma.
J Thorac Dis. 2013;5:E254-E307.
39.
Scherpereel A, Astoul P, Baas P, et al. Guidelines of the
European Respiratory Society and the European Society of
Thoracic Surgeons for the management of malignant pleural
mesothelioma. Eur Respir J. 2010;35:479-95.
40.
Attanoos RL, Gibbs AR. The comparative accuracy of different
pleural biopsy techniques in the diagnosis of malignant
mesothelioma. Histopathology. 2008;53:340-4.
41.
Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy
versus CT-guided cutting-needle biopsy for diagnosis of
malignant disease in pleural effusions: a randomised
controlled trial. Lancet. 2003;361:1326-30.
42.
Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, et
al. Medical thoracoscopy vs CT scan-guided Abrams pleural
needle biopsy for diagnosis of patients with pleural effusions:
a randomized, controlled trial. Chest. 2010;137:1362-8.
43.
Stigt JA, Boers JE, Groen HJ. Analysis of "dry" mesothelioma with
ultrasound guided biopsies. Lung Cancer. 2012;78:229-33.
44.
Medford AR, Agrawal S, Free CM, Bennett JA. A local
anaesthetic video-assisted thoracoscopy service: prospective
performance analysis in a UK tertiary respiratory centre. Lung
Cancer. 2009;66:355-8.
45.
Rodríguez-Panadero F. Medical thoracoscopy. Respiration.
2008;76: 363-72.
46.
Walters J, Maskell NA. Biopsy techniques for the diagnosis of
mesothelioma. Recent Results Cancer Res. 2011;189:45-55.
47.
Greillier L, Cavailles A, Fraticelli A, et al. Accuracy of pleural
biopsy using thoracoscopy for the diagnosis of histologic
subtype in patients with malignant pleural mesothelioma.
Cancer. 2007;110:2248-52.
48.
Kao SC, Yan TD, Lee K, et al. Accuracy of diagnostic biopsy for
the histological subtype of malignant pleural mesothelioma.
J Thorac Oncol. 2011;6:602-5.
49.
Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin
concentrations in malignant pleural mesothelioma:
relationship to tumour volume, clinical stage and changes in
tumour burden. Clin Cancer Res. 2011;17:1181–1189.
50.
Rodríguez Portal JA. Asbestos-related disease: screening and
diagnosis. Adv Clin Chem. 2012;57:163-85.
51.
Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for
diagnosing malignant pleural mesothelioma: an individual
patient data meta-analysis. J Clin Oncol. 2012;30:1541-9.
52.
Hooper CE, Morley AJ, Virgo P, et al. A prospective trial
evaluating the role of mesothelin in undiagnosed pleural
effusions. Eur Respir J. 2013; 41: 18–24.
53.
Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values
of soluble mesothelin-related peptides for malignant
pleural mesothelioma: updated meta-analysis. BMJ Open.
2014;4:e004145.
54.
Pantazopoulos I, Boura P, Xanthos T, Syrigos K. Effectiveness
of mesothelin family proteins and osteopontin for malignant
mesothelioma. Eur Respir J. 2013;41:706-15.
55.
Pass HI, Levin SM, Harbut MR, et al. Fibulin-3 as a blood and
effusion biomarker for pleural mesothelioma. N Engl J Med.
2012;367:1417-27.
56.
Creaney J, Dick IM, Meniawy TM, et al. Comparison of fibulin-3
and mesothelin as markers in malignant mesothelioma.
Thorax. 2014 Oct;69(10):895-902.
57.
Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of
the international association for the study of lung cancer
mesothelioma database. J Thorac Oncol. 2012;7:1631.
58.
van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P.
Malignant pleural mesothelioma: the standard of care and
challenges for future management. Crit Rev Oncol Hematol.
2011;78:92-111.
59.
McCormack PM, Nagasaki F, Hilaris BS, Martini N. Surgical
treatment of pleural mesothelioma. J Thorac Cardiovasc Surg.
1982 Dec;84:834-42.
60.
Flores RM. Surgical options in malignant pleural mesothelioma:
extrapleural pneumonectomy or pleurectomy/decortication.
Semin Thorac Cardiovasc Surg. 2009;21:149-53.
61.
Wolf AS, Daniel J, Sugarbaker DJ. Surgical techniques
for multimodality treatment of malignant pleural
mesothelioma:
extrapleural
pneumonectomy
and
pleurectomy/decortication. Semin Thorac Cardiovasc Surg.
2009;21:132-48.
62.
Rena O, Casadio C. Extrapleural pneumonectomy for early
stage malignant pleural mesothelioma: a harmful procedure.
Lung cancer. 2012;77:151-155.
63.
Sugarbaker DJ, Garcia JP. Multimodality therapy for
malignant pleural mesothelioma. Chest. 1997;112:272S-
5S.
64.
Richards WG, Zellos L, Bueno R, et al. Phase I to II study of
pleurectomy/decortication and intraoperative intracavitary
hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol.
2006;24:1561-7.
65.
Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for
malignant pleural mesothelioma: Results from an EORTC
phase II multicentre trial. Eur Respir J. 2010;36:1362-9.
66.
Flores RM, Pass HI, Seshan VE, et al. Extrapleural
pneumonectomy versus pleurectomy/decortication in the
surgical management of malignant pleural mesothelioma:
results in 663 patients. J Thorac Cardiovasc Surg.
2008;135:620-6.
67.
Halstead JC, Lim E, Venkateswaran RM, Charman SC, Goddard
M, Ritchie AJ. Improved survival with VATS pleurectomy-
decortication in advanced malignant mesothelioma. Eur J
Surg Oncol. 2005;31:314–20.
68.
Srivastava V, Dunning J, Au J. Does video-assisted
thoracoscopic decortication in advanced malignant
mesothelioma improve prognosis? Interact Cardiovasc Thorac
Surg 2009;8(4):454-6.
69.
Weyant MJ. Is it time to consider pleurectomy and
decortication as the only surgical treatment for malignant
pleural mesothelioma? J Thorac Oncol. 2012;7:629–30.
70.
Martin-Ucar AE, Nakas A, Edwards JG, Waller DA. Case-
[Aspectos diagnósticos y terapéuticos en el mesotelioma pleural maligno - Dr. Francisco Rodríguez P.]